What is the current evidence on pharmacological and device-based interventions for preventing heart failure after acute myocardial infarction?
This review provides a comprehensive summary of the current evidence regarding the use of foundational heart failure therapies and devices to prevent heart failure following an acute myocardial infarction.
In patients with acute myocardial infarction (MI), heart failure (HF) is one of the most common complications that is associated with a significant burden of mortality and healthcare resources. The clinical benefits of key HF drugs, the so-called "4 pillars" or "fantastic 4", namely β-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and sodium-glucose cotransporter 2 inhibitors, have been established in patients with HF with reduced ejection fraction, whereas the effects of these drugs are not comprehensively appreciated in patients with acute MI. This review summarizes current evidence on pharmacological and device-based interventions for preventing HF after acute MI.
Saito et al. (Thu,) studied this question.